Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Helen Chapel

Helen Chapel

Professor of Clinical Immunology

Primary immunodeficiencies (PIDs) in adults and children are rare disorders due to failure of the immune system - sometimes inherited as a single gene defect in infants but without evidence of inheritance in adults.
Oxford hosts the largest clinic for adult patients with common variable immunodeficiency disorders [CVIDs], which constitute the commonest forms of symptomatic immunodeficiency. These antibody failure syndromes are of unknown aetiology and likely to be polygenic in nature.

Clinical and laboratory research over the last 25 years has resulted in data enabling the definition of four distinct clinical phenotypes leading to improved prognosis and outcome prediction. Genetic studies are ongoing in these different phenotypes as well as functional studies of blood and bone marrow, to determine pathogenesis, so that improved treatments can be used for the wide ranging complications seen in CVID patients. Current therapy depends on replacing missing antibodies that protect against bacterial infections; details of optimal dosing have been published and are being incorporated into guidelines world-wide.

Recent publications

Defining B-cell defects and correlation with complications in patients with common variable immune deficiency.

Journal article

Chapel H. and Patel S., (2019), J Allergy Clin Immunol, 144, 654 - 655

Correction to: Imaging of Bronchial Pathology in Antibody Deficiency: Data from the European Chest CT Group.

Journal article

Schütz K. et al, (2019), Journal of clinical immunology

Imaging of Bronchial Pathology in Antibody Deficiency: Data from the European Chest CT Group.

Journal article

Schütz K. et al, (2019), J Clin Immunol, 39, 45 - 54

Correction to: Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials.

Journal article

Ballow M. et al, (2018), Journal of clinical immunology, 38, 539 - 539

Ralph Josiah Patrick Wedgwood (1924-2017).

Journal article

Ochs HD. et al, (2018), J Clin Immunol, 38, 153 - 154